| Date | Title | Description |
| 22.06.2020 | GI DYNAMICS, INC.
GI Dynamics : Stockholders Approve Delisting from the Official List | BOSTON and SYDNEY - 22 June 2020- GI Dynamics® Inc. (ASX:GID) ('GID' or the 'Company'), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, announces that it held its Special Meeting of St... |
| 19.06.2020 | GI DYNAMICS, INC.
GI Dynamics : Placement of $750,000 Unsecured Convertible Promissory Note & Update on Potential Financing and Special Meeting | BOSTON and SYDNEY - 19 June 2020- GI Dynamics® Inc. (ASX:GID) ('GID' or the 'Company'), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce that it has issued a US$7... |
| 21.05.2015 | Study: GI Dynamics’ Endobarrier comparable to gastric bypass | GI Dynamics (ASX:GID) said this week that its Endobarrier weight loss device is comparable to gastric bypass surgery in terms of glucose metabolism in obese patients with Type II diabetes. The findings were presented at the American Gastroe... |
| 13.04.2015 | GI Dynamics exercises 1-for-10 reverse split | GI Dynamics (ASX:GID) said it conducted a 1-for-10 reverse stock split in an effort to boost its flagging share price.
Investors were paid cash for any resulting fractional shares, while options, restricted stock units and warrants were rou... |
| 09.12.2014 | Acelity snares Smith & Nephew exec Agarwal | Personnel Moves | Acelity said this week that it snared Gaurav Agarwal from Smith & Nephew (FTSE:SN, NYSE:SNN) to fill its newly created role of business & innovation president.
The new position calls for Agarwal to lead the strategic direction for a... |
| 09.12.2014 | GI Dynamics to lay off 10% of workforce | GI Dynamics said yesterday that it’s planning to cut 10% of its workforce as it develops a restructuring plan.
The move includes the departure of longtime CFO Robert Crane effective immediately, according to a press release. Lexington, Mass... |
| 07.10.2014 | GI Dynamics shares plunge on EU sales halt for EndoBarrier device | European regulators temporarily suspended sales of GI Dynamics‘ (ASX:GID) EndoBarrier weight loss device "pending a review of its vigilance and reporting systems," the company said today, sending share prices plummeting in pre-mar... |
| 09.05.2014 | GI Dynamics raises $32M in private placement with group overseas | Medtech funding stories for the week of May 5, 2014 | Weight loss: GI Dynamics raises $32M with private placement May 2, 2014 by Brad Perriello
GI Dynamics said it raised about $31.7 million (A$34.3 million) in a private placement with a group of "sophisticated, professional and accredite... |
| 02.05.2014 | Weight loss: GI Dynamics raises $32M with private placement | GI Dynamics (ASX:GID) said it raised about $31.7 million (A$34.3 million) in a private placement with a group of "sophisticated, professional and accredited investors" overseas.
The Lexington, Mass.-based medical device company, w... |
| 16.10.2013 | Straight Talk About Diabetes: More Tools Needed | Preventative measures should actually include bariatric procedures, he added, noting, “The risk reduction (following bariatric procedures) is anywhere from 22 percent to 70 percent.”
Surgery ‘Powerful Tool’ Against Diabetes
But Dr. Herman, ... |
| 03.10.2013 | Reimbursement process begins in Switzerland, Germany for GI Dynamics’ EndoBarrier | GI Dynamics (ASX:GID) said Swiss and German regulators took the 1st steps toward reimbursement in those countries for its EndoBarrier weight loss and diabetes device.
Lexington-Mass.-based GI Dynamics said the German Institute of Medical Do... |
| 30.07.2013 | Massachusetts-based device company raises $34.76 million to fund US pivotal clinical trial, execute commercial strategy abroad | The company recently announced this oversubscribed private placement with additional investments from a number of existing investors and welcoming several new institutional shareholders to the register.
Lazard Capital Markets, LLC, the lead... |
| 03.07.2013 | Weight loss: GI Dynamics raises $52M, announces share purchase plan | GI Dynamics (ASX:GID) said it’s raised roughly $52.2 million (A$57.5 million) in a private placement and is offering another $2.3 million (A$2.5 million) in a stock purchase plan for existing shareholders.
The Lexington, Mass.-based medical... |
| 21.06.2013 | Weight loss: France bankrolls EndoBarrier cost trial for GI Dynamics | French regulators will fund a trial looking at the cost and utility of the EndoBarrier device for Type II diabetes and weight loss made by GI Dynamics (ASX:GID).
The Lexington, Mass.-based medical device company’s EndoBarrier won CE Mark ap... |
| 18.06.2013 | Weight loss: GI Dynamics adds centers in Europe | GI Dynamics (ASX:GID) said another 5 medical centers in Europe are online with its EndoBarrier weight loss and diabetes device.
The Lexington, Mass.-based medical device company said centers in Spain, Switzerland and 3 in Germany are now im... |
| 27.02.2013 | Weight loss: GI Dynamics hits the market in Israel | GI Dynamics (ASX:GID) earned a thumbs-up from the Israeli Ministry of Health for its EndoBarrie device to treat obesity and Type II diabetes.
Lexington, Mass.-based GI Dynamics said it’s engaged \Lavi-Medical Agencies as exclusive distribut... |
| 05.02.2013 | Diabetes: GI Dynamics touts positive results in “mildly obese” patients treated with EndoBarrier | Medical device maker GI Dynamics (ASX:GID) touted newly published clinical trial data demonstrating that its EndoBarrier gastrointestinal implant can help control blood sugar levels as well as lower cholesterol in patients with Type II diab... |
| 10.01.2013 | Weight loss: GI Dynamics, W.L. Gore settle patent beef | A long-running dispute between W.L Gore & Associates and GI Dynamics (ASX:GID) is over after the medical device companies agreed to settle the beef.
Gore filed the lawsuit in 2010, alleging that it was the co-inventor and co-owner of GI... |
| 09.01.2013 | Diabetes: GI Dynamics inks research deals with Medtronic, GlaxoSmithKline | Weight loss devices maker GI Dynamics (ASX:GID) announced new research partnerships with GlaxoSmithKline (NYSE:GSK) and Medtronic (NYSE:MDT), looking for new data on its EndoBarrier intestinal liner.
The partnership with Medtronic will exam... |
| 23.08.2012 | Diabetes: GI Dynamics’ EndoBarrier goes directly to pivotal trial in U.S., skips pilot | GI Dynamics (ASX:GID) won conditional FDA approval for a U.S. pivotal clinical trial of the EndoBarrier gastrointestinal liner in treatment of diabetes and obesity, skipping the pilot trial process.
The FDA signed off on the overall pivotal... |
| 31.05.2012 | Early stage life science investor Catalyst Health Ventures looks to raise $33M | Portfolio companies include GI Dynamics Inc., Hansen Medical Inc. (NASDAQ:HNSN), Novazyme Pharmaceuticals (acquired by Genzyme in 2001) and 3-D scanning firm Lantos Technologies. Catalyst has also contributed to medical technology incubator... |
| 24.05.2012 | Minimally invasive weight loss device maker quietly raises $2.75 million | Vibrynt’s website provides little information about the device and says only that the company is “dedicated to creating minimally invasive therapies for patients suffering from morbid obesity.” A phone call to CEO Beverly Hess was not immed... |
| 30.08.2011 | IPO: GI Dynamics lands $86 million | GI Dynamics hit its lower benchmark by raising $86 million in its down-under initial public offering.
The Lexington, Mass.-based device company hoped for between $86 million and $102 million through sales of some 72.7 million chess deposito... |
| 30.08.2011 | GI Dynamics lands $86 million Aussie IPO, DePuy lawsuits grow by 350 in Ohio court, MDT’s SynchroMed gets its second class I recall | MassDevice.com +3 | Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This latest feature of MassDevice.com’s coverage highlights our three biggest and most influential stories from the day’s news to make sure you’re u... |
| 24.08.2011 | Will W.L. Gore patent dispute affect GI Dynamics Aussie IPO? | A long-running patent dispute with W. L. Gore & Associates over its flagship EndoBarrier has come to light as GI Dynamics Inc. looks to close its $86 million initial public offering in Australia.
The case, disclosed in a prospectus for ... |
| 03.08.2011 | Weight loss treatment: GI Dynamics looking to raise $102 million (USD) through Australian IPO | GI Dynamics is looking to raise between $80 to $95 million (AUS), which is about $86 million to $102 million (USD), through an initial public offering in Australia.
The company filed a prospectus with Australian regulators this morning, alt... |
| 03.08.2011 | Breaking: GI Dynamics looking to raise $95 million through Australian IPO | GI Dynamics, a Lexington, Mass.-based company, is looking to raise between $80 to $95 million(AUS), which is about $86 million to $102 million, through an initial public offering in Australia.
The company filed a prospectus with Australian ... |
| 07.09.2010 | GI Dynamics touts EndoBarrier’s weight loss results | Patients implanted with GI Dynamics Inc.’s EndoBarrier device reduced their weight by 20 percent and experienced lowered risk for heart attack, according to the latest results of a clinical trial.
The Lexington, Mass.-based company announce... |
| 01.09.2010 | GI Dynamics inks UK distribution deal | GI Dynamics inked a deal for distribution of its EndoBarrier anti-obesity and Type II diabetes device in the United Kingdom.
The Lexington, Mass.-based firm said Hungerford, England-based Elemental Healthcare will distribute the device, a g... |
| 29.03.2010 | Morning Read: VC dollars are chasing obesity | Boston-based Rhythm Pharmaceuticals, which raised $21 million in a Series A round for treatments for metabolic diseases based on hormones that introduce changes to a cell’s metabolism.
ValenTX, of Carpinteria, Calif., raised $22 million to ... |
| 07.01.2010 | Medtronic invests reported $15M in Massachusetts device company GI Dynamics | GI Dynamics’ EndoBarrier gastrointestinal liner is designed to limit food intake and is applied through the mouth into the small intestines. The device works by establishing a barrier between food consumed and the wall of the intestines, pr... |
| 19.02.2009 | GI Dynamics Closes an Additional $15 Million in Series C Financing | - |
| - | Medtronic invests reported $15M in Massachusetts device company GI Dynamics | MINNEAPOLIS, Minnesota — Medtronic Inc. has invested a reported $15 million in GI Dynamics, a Massachusetts company that’s developing a gastrointestinal liner for type 2 diabetes and obesity treatment.
GI Dynamics will use the funding to pu... |
| - | Morning Read: VC dollars are chasing obesity | Highlights of the important and the interesting from the world of healthcare:
VC dollars are chasing obesity: Startups focused on a variety of disorders brought on by obesity having been cashing in with venture capitalists lately, Reuters r... |
| - | Early stage life science investor Catalyst Health Ventures looks to raise $33M | It appears that Catalyst Health Ventures, an investor in early stage healthcare companies, is looking to raise a new fund.
The firm disclosed a $33 million securities offering — with the first sale yet to occur — in a recently filed U.S. Se... |
| - | Massachusetts-based device company raises $34.76 million to fund US pivotal clinical trial, execute commercial strategy abroad | GI Dynamics, Inc., a Lexington, Mass.-based company known for its EndoBarrier Therapy, which it claims can reduce blood-sugar levels and offer weight-loss results in Type 2 Diabetes patients, has raised $34,755,000 in equity and CDIs, accor... |
| - | Minimally invasive weight loss device maker quietly raises $2.75 million | Although it’s trying to keep quiet about its product, a medical device startup developing a new treatment for obesity revealed this week it’s in the middle of raising $5.5 million.
According to a recently filed U.S. Securities and Exchange ... |
| - | Straight Talk About Diabetes: More Tools Needed | This post is part of ongoing coverage of Cleveland Clinic’s 2013 Medical Innovation Summit: Finding Balance through Innovation. Obesity, Diabetes & the Metabolic Crisis.
During a panel discussion with other doctors and drug industry exe... |
